

Invest . Grow . Impact

# **Earnings Presentation**

9M 2025 Financial Results

November 2025



### **Disclaimer**

#### Important Information

Upon receipt of this Earnings Presentation, the accompanying Press Release to Invest, or any oral presentation relating thereto (collectively, the "Information"), and confirmation of subscription to the Offer Shares, you irrevocably agree to be bound by the following terms and conditions:

The Information is confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. If you were not meant to receive the Information or received it illegally by any third party's breach of the aforementioned confidentiality undertaking, you must immediately return it to its owner - that is Amanat Holdings PJSC (the "Company").

The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The Information has not been reviewed, verified, approved and/or licensed by the Central Bank of the United Arab Emirates ("UAE"), Securities and Commodities Authority of the UAE and/or any other relevant licensing or regulatory authority in the UAE including any licensing authority incorporated under the laws and regulations of any of the free zones established and operating in the territory of the UAE, notably the Dubai Financial Services Authority ("DFSA").


The Information does not constitute a recommendation regarding the offering of the Offer Shares. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of the Offer Shares before taking any investment decision with respect thereto. If you do not understand the contents of the Information, you should consult an authorized financial adviser.

Subject to applicable law in the UAE, the Company shall not accept any responsibility whatsoever in relation to the Information and makes no representation or warranty, express or implied, for the contents of the Information, including its accuracy, completeness or verification or for any other statement made or purported to be made in connection with the Company, and nothing in the Information, or this Disclaimer, shall be relied upon as a promise or representation in this respect, whether as to the past, the present, or the future. The Information contains forward-looking statements, including the Company's target return on investment. These statements and any other statements that are not historical fact that are included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future.

The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this Earnings Presentation and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

# Table of Contents

02 03 01 **Executive Summary Healthcare Update Education Update** pg. 4 pg. 9 pg. 12 05 06 04 **Financial Highlights** pg. 22 **Appendix** Recap pg. 18 pg. 24



# **Executive** Summary

# Key Highlights | Strong execution on growth strategy

Continued strong progress across Healthcare and Education, reflecting ongoing delivery on Amanat's long-term strategy and monetization objectives











Strong financial performance in **9M25**, with Revenue and EBITDA from continuing operations up 15% and 49% YoY, respectively





**Total capacity** reached 715 beds in **9M25** from 660 in December 2024. supported by bed expansion in Jeddah and Dhahran

Launched Cambridge Health Group brand, unifying post-acute care across a single brand





Strong enrollments in higher education, with a 12% and 25% increase YoY in students across MDX and NEMA. respectively

Substantial growth in international students. increasing 39%

YoY at MDX





Student and beneficiary increase of 25% YoY at HDC.

supported by ongoing organic expansion

8 SEN facilities opened in 9M25, with **15** under development



Strong cash position given successful sale of NLCS real estate asset for AED 453 million, generating a 1.7x cash-on-cash return

In October 2025. **Almasar Alshamil** Education announced its Intention to Float 30% of its share capital on the Saudi Exchange at a valuation of SAR **2.0 billion** with a total offering size of around SAR 599 million



### Company Overview | Market-leading Healthcare and Education businesses

Established **market-leading businesses** across **Healthcare and Education** in the UAE and KSA with monetization opportunities progressing well

### Cambridge Health Group



Provider of **Post-Acute Care** in the GCC



AUM - AED 1.4 BN

Post Acute Care Provider





Acquired in February 2021

6 Hospitals 715 beds









# Almasar Alshamil Education



Provider of **Special Education and Care Needs Services** in KSA

AUM - AED 0.3 BN

Acquired in October 2022

**14** Schools, **39** Daycare and Rehab Centers **c. 8.0K** Beneficiaries



Special Education and Care Provider





Provider of **Higher Education** in UAE

**AUM - AED 0.4 BN** 



Acquired in **August 2018** 

1 University c. 6.4K Students

Higher Education















Acquired in March 2018

2 Universities c. 13.6K Students




**Corporate Training** 









# Company Overview | AED 2.6 billion in AUM with AED 0.9 billion of cash and further funds available for deployment







# Financial Performance Snapshot | Revenue from continuing operations increased 15% YoY, with EBITDA from continuing operations up 49% YoY

GROUP REVENUE FROM CONTINUING OPERATIONS

9M25 AED 622.1 MN

(+15% vs. 9M24)

GROUP EBITDA FROM CONTINUING OPERATIONS

9M25 AED 260.9 MN

(+49% vs. 9M24)

GROUP PROFIT
BEFORE TAX FROM
CONTINUING OPERATIONS

9M25 AED 174.8 MN


(+60% vs. 9M24)


GROUP PROFIT FROM CONTINUING OPERATIONS

9M25 AED 164.7 MN

(+73% vs. 9M24)

# GROUP REVENUE FROM CONTINUING OPERATIONS \* AED MN 6x 680 796 542 622 413 513 414 542 622 FY19 FY20 FY21 FY22 FY23 FY24 9M249M25





9M25 Revenue Growth Rates vs. \*

9M21	9M22	9M23	9M24
118%	81%	33%	15%

9M25 EBITDA Growth Rates vs. \* (2)(3)

9M21	9M22	9M23	9M24
82%	82%	7%	10%

9M25 Net Profit Before Tax Growth Rates vs. \*(2)(3)


9M21	9M22	9M23	9M24
67%	112%	4%	0%

For FY 2023, FY 2024 and 9M 2025, the figures represent the Group's results excluding discontinued operations

FY 2021 Group EBITDA of AED 147 MN and profit before taxes of AED 90 MN presented above exclude impact of gain on disposal of divested investees.

Excludes impact of gain on disposal of divested investees for 9M 2021

Excludes impact of gain on disposal of NLCS for 9M 2025



# Healthcare Update

# Healthcare Strategy | Development pipeline to deliver over 1,000 beds in the medium-term to help address growing care demand



#### Healthcare

Launched Cambridge Health Group Brand, laying the foundation for its next stage of growth

UAE	KSA	PPP / Management Agreements	Acquisitions		
<b>3593</b>			$\oplus$		
	>1,000 beds targeted in the med	dium-term (715 current capacity)			
Expand outpatient revenues	Capacity increase to 200 beds in Jeddah and 70 in Dhahran	Commenced ZHO PPP in UAE operating an additional 80 beds	Explore complementary bolt-on acquisitions at attractive		
Continue to diversify into complementary service lines	completed	in 2024	multiples		
such as orthopedics and mental health Enter into further referral	Khobar facility ramp-up ongoing, additional 40 beds being operationalized	Continue to explore management agreements aligned with business strategy			
agreements with Acute Care providers	Further expansion opportunities under assessment across the Kingdom				
Explore further opportunities in  Dubai and the Northern  Emirates	i i i i i i i i i i i i i i i i i i i				

### Post-Acute Care



#### **Date of Acquisition**

CMRC Feb 2021 merged with Sukoon in Apr 2023; rebranded to Cambridge Health Group in October 2025

#### Investment

CMRC AED 873 MN – Sukoon AED 161 MN <sup>(1)</sup>

#### **Specialization**

Post-Acute Care, Long-Term Care, & Rehabilitation



**6** Hospitals



**715** Beds



**55**-bed capacity increase in 9M25


#### **Operational Highlights**

- In October 2025, CMRC rebranded as Cambridge Health Group, unifying Amanat's post-acute care businesses under one regional identity.
- The rebrand supports Cambridge's expansion plan, targeting 1,000 operational beds in the medium term across the UAE and Saudi Arabia.
- Total capacity reached 715 beds in September 2025 from 660 in December 2024, supported by bed expansions in Jeddah and Dhahran.
- Further growth opportunities are under review across KSA including expansions at existing facilities.


#### **Financial Highlights**


- 9M25 revenue increased 6% YoY to AED 289.8 million, with capacity expansions at Dhahran, Khobar and Jeddah resulting in growth at each facility.
- EBITDA increased by 11% YoY to AED 68.8 million in 9M25 and 20% excluding Khobar to AED 75.4 million, driven by newly expanded facilities contributing to profitability.
- EBITDA margins strengthened to 24% (incl. Khobar) from 23% in 9M24, demonstrating ongoing delivery of the Group's strategy.
- Profit before tax decreased to AED 31.6 million, down 9% YoY, reflecting the impact of ramp-up losses at Khobar. Excluding Khobar, profit before tax increased 21% to AED 44.6 million.

#### **AUM I AED 1.4 BN**




**PROFIT BEFORE** 







<sup>(1)</sup> Sukoon initial acquisition was completed in three phases, the first in August 2015, the second in February 2016 and the third in April 2023 (2) Average revenue per patient day excludes ZHO in UAE (3) YoY % change excluding Khobar (4) Excluding 3rd party finance cost associated with acquisition finance



# **Education Update**

# Education Strategy | The region's first integrated education business



#### **Education**

In October, **Almasar Alshamil Education** announced its **Intention to Float** on the Saudi Exchange at a valuation of **SAR 2.0 billion** with a total offering size of **SAR 599 million**.

Ramp-up Launch new existing facilities SEN facilities		Grow enrollments in higher education	New growth initiatives		
شرگة تنمية الرنسان شرگة تنمية الرنسان HUMAN DEVLOPMENT CO.	شرگة تذمية الانسان HUMAN DEVLOPMENT CO.	Middlesex University NEMA			
8 new SEN facilities launched in 2025 and 8 in 2024, reflecting continued ramp-up potential  New daycare centers typically take 24 months to ramp up, with accelerated timelines driven by scale, expertise, and industry knowledge	Reached a total of <b>53</b> SEN facilities at HDC, comprising <b>39</b> daycare centers and <b>14</b> schools   Further <b>15</b> SEN facilities under development, supported by fully funded SAR <b>100</b> million+ expenditure plan   Expanding SEN school network across the UAE and KSA	Target international students with results already seen at MDX where international base has increased 39% YoY New programs geared towards job market needs including launch of London Sports institute last quarter	Almasar partnership to establis  Heriot-Watt University Saudi Arabia, expanding higher- education presence in KSA   Expansion into 24/7 residential SEN services		

# Education | Strong growth in number of students and beneficiaries





3 Universities and 14 SEN Schools, 39 daycare and rehab centers



**c. 28K** Students and Beneficiaries




AED 216.3 MN EBITDA


#### **Strategic Update**


- Total students and beneficiaries rose 22% YoY to a record 28.0k, driven by strong growth in the number of international students and HDC expansion.
- 8 new SEN facilities launched in 2025, with a further 15 under development, supported by fully funded SAR 100 million+ capital expenditure plan.
- Almasar signed non-binding heads of terms to establish partnership with Heriot-Watt University to establish Heriot-Watt University Saudi Arabia, expanding higher-education presence in the Kingdom.
- Ongoing consolidation of NEMA and MDX's leadership in the private higher education markets in Abu Dhabi and Dubai.


#### **Key Highlights**

- Revenue increased 24% YoY to AED 332.3 million, driven by:
  - 25% beneficiary growth at HDC from addition of new daycare centers and schools
  - 12% student growth at MDX (international students +39%)
- EBITDA rose 57% YoY to AED 216.3 million, partially offset by costs associated with Almasar's head office and SEN facility ramp-up.
- Profit before tax rose 61% to AED 174.8 million, driven by the successful divestment of the NLCS real estate asset.









<sup>\*</sup> Head Office costs includes purchase price amortization of AED 4.2 million in the current and prior year-to-date



# Middlesex University Dubai



#### **Date of Acquisition**

August 2018

#### Investment

**AED 419 MN** 

#### **Specialization**

Undergraduate & Postgraduate



**1** University (2 campuses)



c. 6.4K Students



#### **Operational Highlights**


- Delivered 12% YoY student growth with international students growing 39% YoY now comprising 51% of the student body.
- Largest private University in Dubai by enrollments for the 5th year running.
- Continuously increasing international reach, strengthening recruitment capabilities and assessing opportunities to expand breadth of offering.

#### **Financial Highlights**

- Strong revenue growth of 24% YoY in 9M25, driven by record enrollments and higher tuition income.
- 9M25 EBITDA increased 21% to AED 61.7 million, reflecting top-line growth, with Profit Before Tax increasing to AED 44.6 million (+17% YoY).


- Launched The London Sports Institute, offering cutting-edge education, professional training, and applied research in sport science, further enhancing value proposition.
- Granted institutional licensure by the Commission for Academic Accreditation of the UAE's MOHESR.
- Expanded footprint in Dubai Knowledge Park campus to accommodate enrollment growth and improve availability of study and social spaces.
- New daytime MBA program, primarily offered at the DIAC campus.


#### **AUMIAED 0.4 BN**





#### **Portfolio Management Update**







# **Human Development Company**



#### **Date of Acquisition**

October 2022

#### Investment

AED c. 262 MN

#### **Specialization**

Special Education and Care



14 Schools,39 daycareand rehab

centers



**c. 8.0K**Beneficiaries



#### **Operational Highlights**

- Number of beneficiaries increased by 25% YoY to c. 8.0k:
  - o Daycare centers: c. 6.6k
  - o Schools: c. 1.4k
- 8 new SEN facilities launched in 2025, with a further 15 under development, supported by fully funded SAR 100 million+ capital expenditure plan.
- Continuing to explore further residential SEN facilities.


#### **Financial Highlights**

- Revenue growth of 23% YoY driven by expansion of daycare center network and beneficiary growth.
- EBITDA of AED 56.0 million (37% margin), an increase of 18% YoY, supported by an increase in beneficiaries and facilities.
- Profit before tax of AED 34.6 million (23% margin), down 8% YoY, impacted by ongoing facility expansions and the seasonal impact of the summer recess

#### **Portfolio Management Update**


- Assessing and implementing organic and inorganic growth initiatives to grow number of centers and schools.
- Exploring opportunities for expansion across the GCC, including expansion into private clinics and further residential developments.


#### **AUMIAED 0.3 BN**





# PROFIT BEFORE TAX







### **NEMA** Holding



#### **Date of Acquisition**

March 2018

#### Investment

**AED 330 MN** 

#### **Specialization**

Undergraduate & Postgraduate: Corporate Training



**2** Universities (5 campuses)



c. 13.6K Students



**AED 140.4 MN EBITDA** 

#### **Operational Highlights**

- 25% increase in student numbers across Abu Dhabi University and Liwa University.
- Liwa College transitioned into Liwa University, following MOHESR's approval in May 2025.
- Introducing new programs/courses in line with market needs.
- Increase in academic quality and recognition, with Abu Dhabi University ranked among the top 200 universities globally in 2025


#### **Financial Highlights**

- 9M25 Revenue reached AED 508.8 million; 31% YoY growth driven by strong enrollments at both Abu Dhabi University and Liwa University.
- EBITDA increased 30% YoY to 140.4 million, with profit before tax of AED 88.2 million, increasing 83% YoY.


#### **Portfolio Management Update**


- Launching new Al Ain campus of Liwa University, with an expanded capacity of c. 2,000 students upon completion.
- NEMA Holding acquired Biz Group a leading regional provider of corporate training, digital learning and team building.
- Assessing opportunities to optimize value from the real estate assets of the group, including successfully leasing out the vacant Al Bahia campus to a third-party lessee.
- Expanding tech-based offering at the Knowledge Group, catering to the growing demand for digital learning solutions.
- Assessing organic and inorganic growth opportunities including expanding the training offering in KSA.

#### **AUMIAED 0.4 BN**










<sup>\*</sup> NEMA fiscal year ends on 31st August; results are presented based on Amanat's fiscal year ending 31 December



# **Financial** Highlights



# Statutory Profit and Loss

AED MN	9M 2024	9M 2025	%
Continuing Operations			
Revenue	541.9	622.1	15%
Direct Costs	(316.4)	(376.4)	(19)%
Gross Profit	225.5	245.8	9%
General, Selling and Admin Expenses	(172.4)	(203.3)	(18)%
Share of Result of Associate	13.1	25.6	95%
Income from Finance Lease	24.0	20.3	(16)%
Gain on Disposal of Finance Lease	0.0	68.3	(10)/0
Other Operating Income	26.3	28.9	10%
Operating Profit	116.4	185.5	59%
Operating Profit Margin	21%	30%	2370
Finance Income	16.9	12.7	(25)%
Finance Costs	(24.4)	(23.4)	4%
Tillance costs	(24.4)	(23.4)	470
Profit for the Period before Tax from Continuing Operations	109.0	174.8	60%
Tax and Zakat	(13.9)	(11.6)	17%
Deferred Taxes	0.0	1.5	0%
Profit for the Period from Continuing Operations	95.1	164.7	<b>73</b> %
Profit Margin from Continuing Operations	18%	<b>26</b> %	
Discontinued Operation			
Loss from Discontinued Operation	(16.7)	(39.3)	>(100)%
Profit / (Loss) for the Period	78.4	125.4	60%
Attributable to:			
Equity holders of the Company			
Profit from Continuing Operations	81.1	149.4	84%
Loss from Discontinued Operations	(11.2)	(35.2)	>(100)%
	70.0	114.2	63%
Non-controlling Interests			
Profit from Continuing Operations	13.9	15.3	10%
Loss from Discontinued Operations	(5.5)	(4.1)	25%
· ·	8.4	11.1	0%
EBITDA from Continuing Operations	175.1	260.9	49%
EBITDA Margin	32%	42%	
Adjusted EBITDA from Continuing Operations	150.2	169.1	13%
Adjusted EBITDA Margin	28%	27%	

- YoY revenue from continuing operations growth of 15% to AED 622.1 million in 9M25 driven by strong performance in Education, where revenue increased 24% YoY, and 6% YoY revenue growth in Healthcare, reflecting execution on Amanat's long-term strategy
- YoY EBITDA from continuing operations growth of 49% to AED 260.9 million 9M25, driven by the gain from the NLCS real estate asset divestment and strong growth in Healthcare and Education
- Profit from continuing operations increased by 73% YoY to AED 164.7 million in 9M25 due to the positive impact of the NLCS real estate asset divestment
- Finance income declined by 25%, due to lower average cash balances during the period which was positively offset by the NLCS proceeds and lower market rates on Fixed Deposits
- Share of results from associates rose 95% YoY, driven by growth at NEMA
- Malaki Specialist Hospital (MSH) fully ceased operations, with impairment losses of AED 26.8 booked based on the current estimate of fair value




### Statutory Consolidated Balance Sheet | Selected highlights

AED MN	FY-24	9M-25	%
Property and Equipment	625.7	645.1	3%
Right-of-Use-Assets	172.5	198.3	15%
Goodwill and Intangible Assets	1,394.8	1,386.4	(1)%
Investments in associates	397.5	414.2	4%
Finance Lease Receivables	388.6	0.0	(100)%
Trade and Other Receivables	322.5	355.4	10%
Other Financial Assets	36.4	17.3	(53)%
Cash and Bank Balances	503.0	910.8	81%
Assets held for sale	68.5	39.1	100%
Total Assets	3,909.4	3,966.5	1%
Financing from Banks and Overdrafts	338.4	314.9	(7)%
Lease Liabilities	193.1	217.4	13%
Provisions, Accounts and Other Payables	429.2	480.0	12%
Liabilities directly associated with assets held for sale	129.5	55.0	100%
Total Liabilities	1,090.2	1,067.4	(2)%
Equity	2,819.2	2,899.1	<b>3</b> %

- Total assets increased 1% to AED 3,966.5 million, reflecting continued investment and strong liquidity
- Property and Equipment (PPE) rose 3%, mainly due to additions in leasehold improvements related to expansion initiatives at HDC, partly offset by depreciation charges during the period
- Right-of-use assets increased 15%, reflecting the impact of new leases and ongoing expansion projects
- Trade and other receivables grew 10%, driven by new semester billings at MDX and ramp-up activity at Khobar
- Cash and bank balances increased 81% to AED 910.8 million, supported by proceeds from the NLCS real estate divestment
- Provisions, accounts and other payables rose
   12%, reflecting timing differences related to new academic fee billings in the Education business
- 3% increase in Equity to AED 2,899.1 million, supported by profitability and disciplined balance sheet management, underscoring Amanat's strong financial position and capacity to fund future growth


# Cashflow and Net Debt | AED 911 million of cash with additional leverage potential



#### Summary

Movement in cash and bank balances driven by:

- AED 453 million inflow from successful NLCS real estate divestment
- Positive operating cashflows (AED 125 million)
- Capex mainly related to expansion projects in KSA (AED 57 million)
- Dividend from an associate (AED 18 million)
- Net outflows from bank borrowings (AED 81 million)
- Dividends paid to shareholders (AED 40 million)



AED MN	Sept-25
Debt	(315)
Lease Liabilities	(217)
Cash	911
Net Cash/(Debt)	378
Equity	2,899
Gearing (Debt / Debt + Equity)	10%



# Recap



### Recap | Executing on growth and monetization strategy

### Capturing Opportunities in the GCC Healthcare and Education Sectors

Strong financial performance in 9M25 with revenue and EBITDA from continuing operations up 15% and 49% YoY,


respectively

Bed capacity reaching 715 beds and on track to exceed 1,000 beds in the medium term Record enrollments at education driven by 22% growth in total students and beneficiaries, with MDX up 12%, NEMA up 25%, and HDC up 25% year-on-year

with AED 453 million received from the NLCS real estate asset sale providing opportunity to invest in growth and return value to shareholders

Strong cash position

Further long-term shareholder value created through the IPO of Almasar Alshamil Education on the Saudi Exchange



# **Appendix**

# Group Strategy | Established strategy delivering results

### **Strategy**


Invest in and grow market leading companies in attractive sectors with strong structural growth trends and explore opportunities for value creation and monetization

# Identify & Invest Grow Monetize

Identify cash flow generating assets in healthcare and education that have significant growth opportunities and high-quality management teams Establish businesses by developing and executing strategic growth opportunities, to scale business, enhance income generation and maximise value creation

Actively explore business monetization opportunities to unlock value for shareholders and generate capital to invest in attractive targets

### Trading Comparables | Regional comparables trading at c. 18.5x EV / EBITDA



Trading C	omparab	les	
Company	Industry	EV / EBITDA LTM	P/E LTM
Dr. Sulaiman Al Habib Medical Services Group	НС	32.8x	40.1x
Almoosa Health Company	НС	24.9x	35.9x
Dallah Healthcare	НС	22.5x	28.5x
National Medical Care Co.	НС	19.9x	25.2x
Specialized Medical Company	НС	19.5x	32.1x
Mouwasat Medical Services Co.	НС	15.4x	20.9x
Al Hammadi Holding Co.	НС	13.6x	18.8x
Middle East Healthcare Co.	НС	11.8x	13.2x
Burjeel Holding	НС	10.6x	18.2x
Pure Health Holding	НС	8.7x	18.3x
National Co. for Learning and Education	EDU	29.1x	39.7x
Ataa Educational Co.	EDU	16.8x	33.3x
Taaleem Holdings	EDU	15.3x	27.5x
Median		16.8x	<b>27.5</b> x
Average		18.5x	27.1x

Source: S&P Capital IQ as of 30 September 2025



# Financial Performance | Detailed Profit and Loss

AED MN	9M - 24	9M - 25	Change
Middlesex University Dubai	34.4	46.4	35%
NEMA Holding	16.3	27.8	71%
Human Development Company	19.4	18.9	(2)%
North London Collegiate School - Real Estate (Rental Income)	21.9	18.4	(16)%
North London Collegiate School - Real Estate (Gain on Disposal)	0.0	66.3	100%
Head Office Costs	(0.3)	(17.7)	(100)%
Non-recurring Items	0.0	1.2	0%
Education Income	91.6	161.4	76%
Cambridge Health Group	27.6	26.2	(5)%
Malaki Specialist Hospital	(7.0)	(6.4)	9%
Healthcare Income	20.6	19.8	(4)%
Total Education & Healthcare Income	112.2	181.2	62%
Other Income	1.9	0.0	(100)%
Interest and Investment Income	13.8	7.0	(49)%
Non-Recurring Income	4.7	1.0	(79)%
Purchase Price Amortisation	(10.2)	(10.4)	(2)%
Total Income	122.4	178.8	46%
HQ Costs	(27.9)	(24.2)	13%
Portfolio Management Costs	(1.4)	(0.5)	65%
Finance Charges <sup>(1)</sup>	(19.5)	(13.1)	33%
Transaction Related Costs	(1.7)	(0.2)	89%
Non-Recurring Expense - MSH Impairment	0.0	(26.8)	(100)%
Transaction Related Costs (subsidiary & associates)	(1.0)	0.3	>100%
Non-Recurring Expenses	(O.9)	0.0	100%
Profit - Attributable to Equity Holders	70.0	114.2	63%



# Financial Performance | Detailed Profit and Loss by Quarter

AED MN	1Q - 24	2Q – 24	3Q - 24	4Q - 24	FY 24	1Q - 25	2Q - 25	3Q - 25	9M - 25
Middlesex University Dubai	22.7	26.9	(15.2)	25.5	59.8	27.4	34.5	(15.5)	46.4
NEMA Holding	3.9	12.3	0.1	17.2	33.4	6.1	18.8	2.9	27.8
Human Development Company	12.6	4.0	2.8	23.5	42.9	12.6	4.3	2.0	18.9
North London Collegiate School - Real Estate	7.3	7.2	7.3	7.3	29.2	7.1	7.2	4.2	18.4
North London Collegiate School - Real Estate	-	-	-	-	-	-	-	66.2	66.2
Head Office Costs	0	0.0	(0.3)	(7.1)	(7.4)	(5.0)	(6.0)	(6.8)	(17.7)
Non-Recurring Items	0	0.0	0.0	0.0	0.0	0.8	0.2	0.2	1.2
Education Income	46.5	50.4	(5.3)	66.4	158.0	49.1	59.0	53.2	161.4
Cambridge Health Group	9.5	8.2	9.9	14.1	41.6	7.1	6.2	12.8	26.2
Malaki Specialist Hospital	(1.6)	(2.2)	(3.3)	(4.1)	(11.0)	(2.9)	(2.8)	(0.7)	(6.4)
Healthcare Income	7.9	6.0	6.6	10.0	30.6	4.3	3.4	12.1	19.8
Total Education & Healthcare Income	54.5	56.4	1.3	76.4	188.5	53.4	62.4	65.4	181.2
Other Income	0.6	0.6	0.6	0.6	2.5	0.0	0.0	0.0	0.0
Interest and Investment Income	4.6	4.6	4.7	3.0	16.8	2.6	1.6	2.8	7.0
Non-Recurring Income	0.1	0.1	4.6	(4.4)	0.3	0.1	0.2	0.7	1.0
Purchase Price Amortisation	(3.5)	(3.3)	(3.4)	(3.4)	(13.6)	(3.4)	(3.5)	(3.5)	(10.4)
Total Income	56.2	58.4	7.8	72.2	194.5	52.7	60.7	65.4	178.8
HQ Costs	(8.9)	(9.3)	(9.7)	(6.2)	(34.0)	(9.2)	(9.0)	(6.0)	(24.2)
Portfolio Management Costs	(0.3)	(0.6)	(0.5)	0.0	(1.4)	(0.2)	(0.2)	(O.1)	(0.5)
Finance Charges <sup>(1)</sup>	(5.9)	(7.1)	(6.5)	(6.7)	(26.1)	(5.4)	(4.6)	(3.2)	(13.1)
Transaction Related Costs	(0.3)	(O.4)	(1.0)	(1.1)	(2.8)	(O.1)	0.0	(O.1)	(0.2)
Transaction Related Costs (subsidiary & associates)	(O.1)	(0.6)	(0.3)	(1.4)	(2.4)	0.0	0.3	0.0	0.3
Non-Recurring Expense - MSH Impairment	0.0	0.0	0.0	(11.0)	(11.0)	0.0	0.0	(26.8)	(26.8)
Non-Recurring Expense	0.0	0.0	(0.9)	0.0	(0.9)	0.0	0.0	0.0	0.0
Profit - Attributable to Equity Holders	40.6	40.4	(11.1)	45.9	115.8	37.7	47.3	29.2	114.2

James Anderson | Teneo investor.relations@amanat.com



Stay Connected in X o







amanat.com